To improve the efficacy of risk-adapted melphalan (MEL) in patients with amyloidosis (AL), we conducted a phase II trial using bortezomib and dexamethasone (BD) as consolidation. Forty untreated patients with renal (70%), cardiac (65%), liver/ gastrointestinal (15%) or nervous system (13%) AL were assigned MEL 100, 140 or 200 mg/m 2 based on age, renal function and cardiac involvement. Hematological response was assessed at 3 months post stem cell transplant (SCT); patients with less than complete hematological response (CR) received BD consolidation. Four patients with advanced cardiac AL died within 100 days of SCT (10% treatment-related mortality). Survival at 12 and 24 months post treatment start was 88 and 82% overall and was 81 and 72% in patients with cardiac AL. At 3 months post SCT, 45% had X partial response (PR) including 27% CR. Twenty-three patients received consolidation and in 86% response improved; all patients responded in one cycle. At 12 and 24 months, 79 and 60% had X PR, 58 and 40% CR. Organ responses occurred in 55 and 70% at 12 and 24 months. Eight patients relapsed/progressed. One patient with serologic progression had organ impairment at time of progression. In newly diagnosed AL, BD following SCT rapidly and effectively improves responses resulting in high CR rates and maintained organ improvement.
INTRODUCTION
Light-chain amyloidosis (AL) is a clonal plasma cell disorder and organ disease associated with the production of pathological free light chains (FLC). 1 Misfolded FLCs deposit in the form of amyloid in affected organs such as the heart, kidney, liver or gastrointestinal tract and the peripheral or autonomic nervous systems. Amyloid causes morbidity by impairing organ function and patients with cardiac involvement have shortened survival. 2 Organ dysfunction can be reversed if the synthesis of the amyloidogenic protein is shut down. 3 Treatment of AL is aimed at eradicating the pathological plasma cells and reducing the circulating FLC so that organs can improve and survival can be extended. 2, 4 High-dose melphalan (MEL) and autologous stem cell transplant (SCT) induce responses in patients with AL. 2, 4, 5 Despite being effective, this strategy can be toxic in AL patients who have compromised organ function. 5 To deliver high-dose MEL safely, risk adapted dosing has been explored but may be associated with lower response rates. 6 We have incorporated consolidation with novel agents following SCT in AL patients who have persistent clonal plasma cell disease in an effort to increase response rates. In our prior phase II study, thalidomide and dexamethasone were administered following risk adapted MEL and SCT to patients who did not achieve a complete hematological response (CR). 7 At 12 months after SCT, 78% of patients responded including 39% with CR; 42% of patients who received thalidomide and dexamethasone had improved hematological responses. 7, 8 Median progression free survival (PFS) was 40 months; at a median of 52 months of follow-up 69% of patients were alive. 7, 8 The reversible proteasome inhibitor bortezomib is active and well-tolerated in relapsed AL , resulting in durable hematological responses in over two-third of patients. 9 In the current trial, we treated patients who had not achieved CR following risk adapted MEL and SCT with bortezomib and dexamethasone (BD) as consolidation. We found that BD effectively improves hematological responses post transplantation and results in high hematological response rates, durable organ improvement and promising overall survival (OS) for newly diagnosed transplanteligible patients with AL.
SUBJECTS AND METHODS

Patient eligibility
Patients with untreated AL were eligible for enrollment on this Institutional Review Board approved phase II clinical trial (NCT822). Patients required a histological diagnosis of amyloid, clonal plasma cell disease and symptomatic involvement of no more than two major organ systems.
Hereditary AL was excluded by gene sequencing of commonly inherited amyloidogenic proteins in patients who met previously defined clinical criteria. 11 Adequate organ function was required including serum bilirubin p2.0 mg/dl; pulmonary diffusion capacity X50% and left ventricular ejection fraction X45%. Patients were excluded for uncompensated New York Heart Association (NYHA) class 3 or greater congestive heart failure, symptomatic cardiac arrhythmia or cardiac syncope within 60 days of enrollment. Patients with symptomatic multiple myeloma (430% plasma cells or lytic lesions on skeletal survey) or soft tissue amyloid as the only organ involvement were ineligible.
Study design
Stem cells were mobilized with granulocyte colony-stimulating factor alone. Patients with cardiac arrhythmias or orthostatic hypotension were admitted and monitored on telemetry during stem cell mobilization and collection. Patients were assigned to one of three MEL dose levels (MEL 200 mg/m 2 , 140 mg/m 2 or 100 mg/m 2 ) based on age, cardiac involvement and renal function as defined by 24-hour creatinine clearance p50 ml/min ( Figure 1 2 (only) as a 4-day pulse, up to 3 pulses each month for 6 months. Patients were assessed monthly following SCT through 12 months post SCT, every 2 months for the subsequent year and then every 3 months until progression. Toxicity was scored using National Cancer Institute common toxicity criteria (CTCAEv3.0).
Response assessment
Hematological response was assessed at 2, 3, 12 and 24 months following SCT in accordance with the guidelines established by the 10th Annual International Symposium on Amyloid and AL. 10 A CR required a negative serum and urine immunofixation electrophoresis, normal serum FLC ratio and o5% clonal plasma cells on bone marrow studies; partial response (PR), stable disease and disease progression (PD) was defined as previously described. 10 Organ involvement was defined for each patient by standard and updated criteria. 10, 12 Response was scored at 12 and 24 months following SCT as improved, stable or worsened. 10, 12, 13 Brain natriuretic peptide (BNP) levels were obtained over the course of treatment and changes with therapy were noted. Stable or worsening organ function was defined as previously described but also updated to include cardiac BNP data. 10, [12] [13] [14] 
Biostatistics
The primary end point of this phase II study was the rate of response improvement in patients receiving BD consolidation. Response improvement was defined as any improvement in the response (that is, stable disease to PR/CR or PR to CR) at 12 months compared with post SCT restaging. A single-stage design was used to differentiate between response improvement rates of p45 and X68% using 10% type I and type II errors rates. We planned on accruing 31 patients who received BD and, if at least 18 patients had response improvement, then the treatment was to be declared a success. Response rates were calculated along with exact 95% confidence intervals (CI). Complete restaging studies were performed and overall hematological and organ response rates determined, at 2-3, 12 and 24 months post SCT. OS was defined as time from treatment start until date of death or last follow-up. PFS was defined as time from treatment start until date of progression, death or last follow-up. PFS and OS were estimated using the method of Kaplan-Meier. Differences between categorical variables were assessed using Fisher's exact test. Differences between continuous variables were assessed using the Wilcoxon rank sum test. The associations of BNP and troponin on OS were evaluated using the Cox proportional hazards model. Hazard ratios for these associations are reported. Four of 11 patients with stage 3 cardiac involvement died within 100 days of SCT including one who died during granulocyte colony-stimulating factor mobilization resulting in a treatment related mortality of 10%. Twenty-five patients with persistent clonal plasma cell disease were eligible to receive consolidation with BD; one patient declined and another relocated. The median time from transplant to consolidation was 2.7 months (range 2.0-6.8). Twenty-two patients received a median of 6 cycles of BD consolidation (range 1-6) and one received dexamethasone due to preexisting grade 2 painful neuropathy. Toxicity Grade 3-4 adverse events possibly related to BD consolidation are shown in Table 2 . One patient with advanced cardiac disease (BNP 45000) died during consolidation. Other grade 3 cardiac adverse events included supraventricular tachycardia (N ¼ 1), hypotension (N ¼ 2) and congestive heart failure (N ¼ 1). Grade 3 gastrointestinal toxicity was only seen in one patient who developed abdominal bloating. Grade 2 neuropathy occurred in ten patients and grade 3 in two. Significant (grade 3-4) hematological adverse events included 43% thrombocytopenia, 13% anemia and 4% neutropenia.
RESULTS
Patient characteristics
Hematological responses At 2-3 months post transplant, hematological responses were PR 18% (n ¼ 7), CR 27% (n ¼ 11) and stable disease 45% (n ¼ 18). By intention-to-treat, at 12 months post SCT hematological responses were seen in 79% (95% CI: 65-92%) of patients including 58% who achieved CR (95% CI: 42-75%) ( Table 3) . Of the patients in CR following SCT (N ¼ 11), 10, 45 and 45% received MEL 100, MEL 140 and MEL 200, respectively. No significant difference was seen based on MEL dosing at either 2-3 (P ¼ 0.21) or 12 months post SCT (P ¼ 0.45) ( Table 4) . Of the 23 patients who received consolidation, 21 were assessable for response improvement at 12 months, the primary end point. Eighteen (86%, 95% CI: 64-97%) of these patients achieved better responses at 12 months post SCT, including eight who improved from stable disease to CR, and four from PR to CR. As the number of patients with response 
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improvement met the pre-defined target, the criterion for declaring the regimen effective was met. The maximal FLC response following BD was seen with the first cycle of treatment in 95% of patients and there was no statistically significant association between the number of cycles of BD received and response (P ¼ 0.15), although patients who achieved CR tended to have received fewer cycles (Figure 2 ). Among patients classified as PR at 12 months post SCT, the very good partial response rate was 100% using updated FLC criteria. 14 
Organ responses
By intention-to-treat, 55% (N ¼ 21) of patients had improvement in at least one involved organ by 12 months and 70% (N ¼ 21) by 24 months (Table 3) . When assessed by individual organ, at 12 months post SCT improvement was seen in 9/17 surviving patients with cardiac involvement, 12/23 with renal, 3/5 with hepatic/gastrointestinal and 4/4 with nervous system involvement. By 24 months post SCT, 21 of 22 evaluable patients (7 deceased,10 ongoing and 1 off study) had achieved organ responses including 5/9 (56%) patients with cardiac and 13/15 (87%) with renal involvement. In patients with creatinine clearance X45 ml/min, the median percent reduction of the BNP at 12 and 24 months post transplant was 50% and 77%, respectively. 12 Progression free and overall survival Kaplan-Meier curves of PFS and OS are shown in Figure 3 . The median follow-up of surviving patients is 45 months (range 10-60 months) and the median PFS and OS have not been reached. At 24 months following treatment initiation, 82% of patients are alive and 69% are progression free. Only one patient who met criteria for hematological progression (PD) developed worsening organ function at the time of progression.
Survival of patients with cardiac involvement was 81% at 12 months and 72% at 24 months following initiation of treatment ( Figure 3) . The cardiac patients who died on this trial had baseline median BNP of 638 pg/ml (120-1720 pg/ml) and troponin-I of 0.12 ng/ml (0-0.3 ng/ml) while those who survived had baseline BNP and troponin-I of 105 pg/ml (0-713 pg/ml) and 0 ng/ml (0-0.2 ng/ml), respectively. Higher values of BNP (hazard ratio 1.3; 95% CI: 1.1-1.4, P ¼ 0.0001) and troponin-I (hazard ratio 4.0; 95% CI: 1.9-8.3, P ¼ 0.0002) were independently associated with inferior survival. The OS of patients with stage III cardiac involvement was 50% at 12 months and 36% at 24 months, while all stage I and II patients were alive at 24 months following SCT (Figure 3 ).
DISCUSSION
Risk-adapted MEL and SCT followed by BD is an effective strategy for treating newly diagnosed patients with AL. The majority of patients (79%) achieved hematological responses including over half (58%) who achieved strictly defined CR. Whereas one-third of patients achieved CR with high-dose MEL and SCT alone, 86% of patients with persistent disease improved their response with additional BD consolidation, supporting the activity of this treatment program. Although patients undergoing SCT may achieve maximal hematological responses beyond 2-3 months post SCT, the rapidity of FLC reduction with consolidation suggests that BD accounted for the up-graded responses.
The combination of an alkylator and bortezomib acts synergistically against plasma cells in multiple myeloma, at least in part by downregulation of DNA repair mechanisms after genotoxic chemotherapy. 17 Bortezomib administered following rather than before high-dose MEL results in increased apoptotic plasma cells, 18 and may account for the rapid and high complete response rate seen in 57% (12/21) of our patients who received consolidation following SCT (Figure 2 ). High-dose MEL (on days À 2 and À 1) and bortezomib (1 mg/m 2 days À 6, À 3, þ 1 and þ 4) administered in combination has been studied in 10 patients with AL. 19 Responses were seen in 80% of these selected patients including 67% who achieved CR, 19 which also compares favorably with high-dose MEL alone. 2, 7, 20 In contrast, responders to cyclophosphamide, BD eligible for SCT did not achieve deeper responses after high-dose MEL. 21 At present, the optimal combinations and sequencing of alkylators and proteasome inhibitors in AL require larger phase III studies.
Encouraging response rates have recently been reported in patient with AL treated with cyclophosphamide, BD without highdose therapy. 21, 22 In one series, hematological responses were achieved in 16/17 (94%) patients who were either transplant ineligible (N ¼ 10) or relapsed (N ¼ 17). 21 In a second larger series, responses were achieved in 90% of treatment naive (N ¼ 20) and 74% of relapsed (N ¼ 23) patients. 22 With short follow-up in both studies (21 and 14 months) the durability of these responses cannot yet be determined. 21, 22 On our trial, 85 and 69% of patients had not progressed at 12 and 24 months following treatment initiation (Figure 3) .
High-dose therapy and SCT has been challenged by phase III data showing inferior survival for patients who received high-dose MEL compared with oral MEL and dexamethasone (22.2 vs 56.9 months, P ¼ 0.04). 20 However, 9/37 (24%) patients on their study died within 100 days of transplant highlighting the importance of appropriate patient selection, risk-adapted MEL dosing and supportive measures instituted at centers experienced at caring for AL patients. 7, 20 On the current study, the treatment-related mortality was low (10%), similar to other large single institution studies. 2, 7, 23 Patients with cardiac disease are frequently excluded from stem cell transplant studies. Although early mortality remains a challenge especially for patients with stage III cardiac involvement, 55% of stage III patients in this phase II trial were alive at 12 months, which compares favorably to the median that has been reported, 4-7 months. 15, 24 Recognizing the heterogeneity of this group, we excluded only patients with NYHA stage 3 or 4 heart failure, symptomatic arrhythmias, or cardiac syncope.
Among 11 patients with stage III cardiac disease there were four toxic deaths. Yet, 36% of patients remain alive at 2 years post SCT. Despite the definite value of cardiac biomarker staging, 15 a more discriminatory approach to risk stratification may increase access to clinical trials and help define populations who benefit from consolidation and/or maintenance therapies. 24, 25 On this study BD consolidation was tolerated without unexpected toxicity (Table 2) . Fifty-seven percent of patients experienced X grade 2 neuropathy. The propensity of light-chain amyloid to affect peripheral nerves may predispose patients to neuropathy especially because reliable methods to define peripheral nervous system involvement in AL are lacking. 10 In addition, twice weekly bortezomib likely contributed, 9,26 and we were specifically focused on detecting this toxicity. 27 Although subcutaneous bortezomib has been shown to reduce the incidence of peripheral neuropathy in patients with multiple myeloma, 28 the bioavailability and pharmacokinetics of subcutaneous administration in patients with AL has not been established. In patients with AL who may have heart failure and/or nephrosis, it is not our practice to administer bortezomib subcutaneously. Proteasome inhibitors with different toxicity profiles such as carfilzomib 29 and MLN-9708 30 may be important for patients with AL and studies using these drugs are ongoing. We currently use weekly administration of bortezomib following alkylator therapy.
Durable hematological responses are necessary for restoration of organ function over time and three quarters of patients treated on our study had organ improvement at 2 years following transplant. Interestingly, only half of patients met criteria for organ response in the first year following SCT. Thus resolution of amyloid deposition and/or compensation of involved organs occur very gradually when the FLCs are controlled. 4 Pre-clinical efforts to speed organ recovery have focused on immune-based therapies. [31] [32] [33] Direct targeting of amyloid deposition in combination with cytotoxic therapy may ultimately lead to faster organ and functional improvement as well as better outcomes.
In summary, this phase II study demonstrates that BD administered as consolidation following SCT was an effective therapeutic strategy for patients with newly diagnosed AL. Careful patient selection, risk-adapted MEL dosing and supportive measures rendered treatment safe and increased patient access to SCT and the novel agent bortezomib. With 45 months of followup, responses are durable; however, several questions are raised. With routine FLC assessments we observed that hematological relapse or progression occurs most often in the absence of organ progression. We know that patients who relapse and progress following high-dose MEL alone can be salvaged with bortezomibbased therapy. 9 Yet, we do not know the response rates to bortezomib or other proteasome inhibitors in AL patients who receive bortezomib post SCT or as part of initial therapy. Therefore, research focusing on new drugs for this disease remains essential. Moreover, we do not know whether the PFS in patients who achieve a CR to BD consolidation following SCT is equivalent to CR achieved with alkylator therapy alone. It is possible that BD consolidation results in longer PFS and perhaps consolidation should be considered for all patients following SCT, regardless of response. On the other hand, if PFS is similar, reserving the proteasome inhibitor for the time of relapse for patients who achieve a CR to SCT makes sense. Furthermore, response duration after BD consolidation may be prolonged with further bortezomib treatment and evaluating maintenance therapy in this setting is warranted. Finally, it is also worth studying whether there is a benefit of high-dose therapy when patients respond to initial proteasome inhibitor therapy. We are currently conducting a phase II study using bortezomib in initial therapy, and in consolidation and maintenance in the context of risk-adapted MEL and SCT in order to assess these issues.
